Latest Mesoblast (ASX:MSB) News
Page 4
Page 4 of 5
Mesoblast’s Ryoncil Sales Soar 60% as New $125M Facility Boosts Growth
9 Jan 2026
Mesoblast Secures US$125M Credit Line, Slashes Debt Costs and Boosts Flexibility
30 Dec 2025
Independent Study Finds Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD
12 Dec 2025
Mesoblast Projects 37% Revenue Surge on Ryoncil Sales in Q4 2025
25 Nov 2025
Mesoblast’s RYONCIL Surges with FDA Nod and $30M Quarterly Revenue
25 Nov 2025
Mesoblast Prepares FDA Talks on Rexlemestrocel-L’s Opioid Cessation Promise
5 Nov 2025
Mesoblast’s Ryoncil Revenues Surge 69% Following Key FDA and CMS Milestones
20 Oct 2025
Mesoblast’s Ryoncil Sales Jump 66% After FDA Approval and CMS Reimbursement
7 Oct 2025
Mesoblast Secures US$50M Convertible Note Option to Boost Capital Structure
4 Sept 2025
Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge Amid FDA Milestone
29 Aug 2025
Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge in FY2025
29 Aug 2025